Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 2/20 | 0.36 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | ACAT2 | Q9BWD1 | 1/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.32 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | VCP | P55072 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17757906 | 0.88 | TAAR1 (0.35) | TAAR1ACAT2CCNT1ACHEBACE1 | |
| SCHEMBL17758093 | 0.87 | ACAT2 (0.33) | CARM1PRMT6TAAR1ACAT2CCNT1 | |
| SCHEMBL17757427 | 0.86 | ACAT2 (0.37) | CARM1PRMT6ACAT2CCNT1ACHE | |
| SCHEMBL17757477 | 0.86 | TAAR1 (0.36) | TAAR1ACAT2BRD4 | |
| SCHEMBL17757883 | 0.86 | ACAT2 (0.36) | TAAR1ACAT2CCNT1ACHEBACE1 | |
| SCHEMBL17757474 | 0.86 | MAOB (0.37) | ACAT2CCNT1ACHEBACE1 | |
| SCHEMBL17758082 | 0.85 | EPHX2 (0.41) | OPRM1OPRL1 | |
| SCHEMBL17757886 | 0.84 | ACAT2 (0.42) | ACAT2CCNT1 | |
| SCHEMBL17758095 | 0.84 | CCNT1 (0.33) | CARM1PRMT6ACAT2CCNT1ACHE | |
| SCHEMBL17757433 | 0.84 | ACAT2 (0.33) | TAAR1ACAT2CCNT1BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10647687-B2 | Spiropyrazine derivatives as inhibitors of non-apoptotic regulated cell-death | HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT (GMBH) (DE) | 2020-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10647687-B2 | Spiropyrazine derivatives as inhibitors of non-apoptotic regulated cell-death | AIFM2, BAD, AIFM1 | CARM1 3360/4885PRMT6 4009/4885TAAR1 465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.